Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo

NCT00905372 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00905372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00905372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2009
Completion date
April 30, 2012
Enrollment
1,000 (estimated)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease